GE HealthCare, a leader in breast health technology and diagnostics, is set to showcase its cutting-edge breast cancer detection technology at the 2024 Society of Breast Imaging Symposium in Montreal, Canada, from April 11-14, 2024. The highlight of this year’s event will be the Mobile Mammography Screening Truck, alongside the recently launched MyBreastAI Suite* and Pristina Bright** offerings, exemplifying the company’s commitment to personalized breast cancer imaging solutions.
Breast cancer, affecting one in eight women in their lifetime, underscores the importance of regular mammograms. However, effectiveness can be limited in women with dense breast tissue, who face higher cancer risks. To address this challenge, clinicians increasingly turn to supplemental screening options and AI technologies. GE HealthCare’s MyBreastAI Suite integrates three AI applications to aid in early detection and enhance patient outcomes, while optimizing radiology workflow.
Pioneering Contrast-Enhanced Mammography (CEM) technology, GE HealthCare continues to revolutionize breast diagnostic imaging and biopsy care. With over 200 publications demonstrating its clinical efficacy, CEM remains a game-changer. The company’s Pristina Bright offering further advances breast cancer detection, enabling clinicians to visualize lesions not visible on routine mammograms and perform biopsies within minutes.
Dr. Jordana Phillips, a Radiologist at Boston Medical Center, attests to CEM’s efficacy in improving breast cancer outcomes. She emphasizes its ability to provide additional diagnostic information efficiently and patient-centrically.
As part of its commitment to healthcare accessibility, GE HealthCare will showcase its mobile mammography unit onsite, offering attendees convenient screening opportunities within their workplace environment. The unit features the Senographe Pristina and Invenia ABUS, ensuring accurate and efficient screenings.
Visit booth 301 at the symposium to learn more about GE HealthCare’s personalized breast cancer screening solutions, including Senographe Pristina, Invenia ABUS, SenoBright HD CEM, and Serena Bright.
*MyBreastAI Suite includes GE HealthCare’s Edison Health Services platform, ProFound AI® for DBT, SecondLook for 2D Mammography, and PowerLook® Density Assessment, provided by iCAD. **Pristina Bright includes SenoBright HD, Pristina Serena, and Serena Bright.
[1] Breastcancer.org. Breast Cancer Facts and Statistics. [2] Boyd NF et al. NEJM 2007; 356: 227-36. [3] Bashar, MD Abu; Begam, Nazia1. Breast cancer surpasses lung cancer as the most commonly diagnosed cancer worldwide. Indian Journal of Cancer 59(3):p 438-439, Jul–Sep 2022. [4-8] References for data and studies supporting CEM technology efficacy.
